“Our non-GAAP operating margins remain unchanged at approximately 29%.”

In context

“ook now includes an additional $300 million of headwinds from foreign exchange rates since our previous guidance update for a total impact of roughly $1 billion of foreign exchange headwinds of revenue for the full year compared to our original guidance. Our outlook for gross margin, SG&A and research and development remains unchanged. Our guidance now includes acquired IPR&D and development milestone charges of approximately $670 million, reflecting total charges in the first 9 months of the year. We have not recognized material acquired IPR&D or development milestone charges to date in Q4. And this guidance does not include any impact from the potential acquisition -- for business development or acquisition in the remainder of the year, including pending acquisition of [indiscernible]. Our non-GAAP operating margins remain unchanged at approximately 29%. On a reported basis, operating margin is now expected to be approximately 26%, driven by the intangible asset impairment for our GBA1 Gene Therapy due to change in estimated launch timing. Our non-GAAP range for other income and expense remains unchanged. On a reported basis, other income and expense is now expected to be expensed in the range of $600 million to $700 million, reflecting the net impact of net losses on investments in equity securities during Q3 2022. Our tax rate and EPS in the first 9 months of the year includes a favorable impact of the provision in the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes. Our financial guidance for the full year continues to assume this provision will be deferred or repealed”